{"disease":{"id":"transformed-follicular-lymphoma-tfl","name":"transformed follicular lymphoma tfl"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT07168486","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}